Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Currently unlisted.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| MMG | Ann: First Quarter 2018 Production Report | 23/04/18 | 0 | 44 | |||
|
|||||||
| MMG | Ann: Closure of Register of Members | 20/04/18 | 0 | 39 | |||
|
|||||||
| MMG | Ann: CDI Voting Instruction Form | 20/04/18 | 0 | 37 | |||
|
|||||||
| MMG | Ann: Shareholder Proxy Form | 20/04/18 | 0 | 33 | |||
|
|||||||
| MMG | Ann: Annual General Meeting Circular | 20/04/18 | 0 | 31 | |||
|
|||||||
| MMG | Ann: Annual Report 2017 | 20/04/18 | 0 | 38 | |||
|
|||||||
| MMG | Ann: Notice of Annual General Meeting | 20/04/18 | 0 | 31 | |||
|
|||||||
| MMG | Ann: Monthly Return of Equity Issuer on Movements in Securities | 10/04/18 | 0 | 59 | |||
|
|||||||
See All Discussions
ASX News